Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

432

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Lung CancerPulmonary NeoplasmsSmall Cell Lung Cancer
Interventions
DRUG

SR48692

Trial Locations (14)

Unknown

Sanofi-Aventis Administrative Office, Buenos Aires

Sanofi-Aventis Administrative Office, Macquarie Park

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, São Paulo

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, México

Sanofi-aventis adminsitrative office, Gouda

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, Moscow

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Guildford Surrey

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY